Nasdaq
Everyone’s scared of booze stocks… Why I’m still buyingThis analysis is provided by Eden Bradfeld at BlackBull Research.
One of the things I find interesting is that a lot of people say “why do you like booze stocks so much Eden” and yet many of these same people are at the pub, or buying En primeur from Glengarry Wines. The short answer is — I like stocks that trade at multi-year lows with a predictable product. There is a fairly hysterical article in the FT wondering “Is alcohol the new tobacco?” To which I say, well, tobacco companies are absolute cash machines. The best performing stock in the S&P, of all time, to the best of my knowledge, is Altria.
I know investing in tobacco is not fashionable (and yet, how many people do you see on the street vaping?). I know it goes against “ESG” and the scolds at public health slap you on the hand and say “gosh that is very bad for you!”. But the truth is that tobacco does generate tremendous profits — the net income margin for British American Tobacco is 39.1%. For those in the back, that’s for every $1 you sell, you make 39.1 cents of profit. There’s very few businesses with such fantastic operating margins — Visa’s net income margin is 56%. If I owned only one stock forever, I guess it’d probably be Visa.
My point is — waving your hands about and saying “oh no! Tobacco!” belies the economics of it. The tobacco companies are doing very well, thank you very much. It will come as no surprise that cigarette smoking has been replaced by vaping. To paraphrase Oscar Wilde, news of nicotine’s demise has been greatly exaggerated.
This is not saying to invest in tobacco stocks, but my point is that human habits don’t change. They merely evolve, but the song remains the same.
To be fair — alcohol consumption is declining. But it isn’t declining at a rate that calls for any kind of alarm. Most of the companies I follow — Brown Forman, Diageo, Constellation, etc, reported largely flat sales. It’s also instructive to look to history.
In other words — alcohol consumption has largely normalised in the last few decades. There’s still cause for worry — I think wine is one area of concern, and Cognac is another — both industries need to think about how they introduce younger drinkers to their product. This is why I largely shy away from wine (and why Constellation is selling their wine portfolio). “Evergreens” like Guinness (a Diageo brand) and Jack Daniel’s (a Brown-Forman brand) are predictable.
Once again — a bunch of ratios for ya’ll:
Brown-Forman: 18x fwd earnings
Pernod: 12x fwd earnings
Constellation Brands: 13.25x fwd earnings
And so on… these stocks trade like they are discount retailers in biddlybunk Ohio. They are not. There’s the issue. There’s where value lies. Cigarettes never went away; they became vapes. In my opinion, I don’t see booze going away anytime soon either.
I'll be honest here friends it's not looking good...I'll be honest here friends it's not looking good...
This may have been a Dead Cat Bounce on the NASDAQ:QQQ and AMEX:SPY friends.
GAP fills in both names lead to Bear Flag Breakdowns which in my mind leads to the next leg down.
Rejecting 200DMA on the NASDAQ:QQQ and losing control on the AMEX:SPY
Markets are hanging on slightly, lets see what happens the rest of the week.
Not financial advice
NASDAQ on the first minor pullback of the new bullish wave.Nasdaq / US100 has just started the new bullish wave of the long term Channel Up.
The bottom was made 2 weeks ago and every time the bullish wave crossed over its 4hour MA50, it is expected to make a pullback retest at some point.
This pullback is taking place today.
Whether it replicates the first bullish wave of the Channel Up or the second, the index aims for either a 22.48% total rise or the 1.382 Fibonacci extension.
Both happen to be around the same level.
Buy and target a little under them at 23400.
Previous chart:
Follow us, like the idea and leave a comment below!!
My NQ Long Idea 26/03/2025There is a big technical area that has taken the spotlight in NQ and it is around the 50% fib level with a gap opening.
US economy has seen some strengthening recently with the FED looking neutral-dovish. A price correction may not even occur here it can keep going up continuously the moment we have a conclusive risk-on environment.
Inflation has cooled down from 3.0 to 2.8 and interest rate was held at 4.50 from 4.50.
We are expecting a rate cut of 0.25 bps by Q2 so the market is looking forward to price that in.
I see a potential "buy the rumor" then "sell the news" scenario here. So during the next fomc meeting we may get a small sell off for a price correction then NQ will continue its up momentum.
Technical setup looks good I expect a turbulent price action which will fill the opening gap at the 50% a consolidation here can be healthy for price action before we get a Wyckoff spring.
We have recently exited a bearish channel and entered a new bullish channel which is still in progress but must pay attention to it as we could start trending in that direction.
I may take a short position (for the short term) since I anticipate a correction to the gap at the 50%.
Nasdaq in Correction: Technical Targets and Weekly OutlookWe can observe that Nasdaq has started a new corrective leg since its last recovery in early Q3 2024. Currently, the index is experiencing its first rebound and test of the 20-period moving average (MA20, in green) since this average turned downward. Typically, this scenario triggers a selling reaction, with the first target at the previous low of 19,200. If selling pressure intensifies, the next projections are at 18,300 and 17,900.
However, from a weekly perspective, there is still room for a deeper correction, potentially reaching the 200-period moving average (MA200), which is currently at 15,690. When applying a Fibonacci retracement to the last major bullish leg (Oct 10, 2022 – Feb 17, 2025), we see that the 50% retracement level aligns closely with the weekly MA200 at 16,300.
We know that price movements do not follow a straight line but rather unfold in waves. Given this context, the bias remains bearish, and I see further corrections ahead in the U.S. market.
NASDAQ: Short term Channel Up on critical Resistance.Nasdaq is neutral on its 1D technical outlook (RSI = 49.418, MACD = -276.610, ADX = 37.535) as it has recovered from the oversold state of 2 weeks ago. By doing so, it has formed a Channel Up on the 1H timeframe but as the price hit its top and the 1H RSI has formed a bearish divergence like the previous HH, it is possible to see a quick pullback. As long as the price stays inside the Channel Up, target the 1H MA200 (TP = 19,900). If it crosses above the top of the Channel Up, buy and target the R1 level (TP = 20,650).
## If you like our free content follow our profile to get more daily ideas. ##
## Comments and likes are greatly appreciated. ##
US100 Short Fear rises of FED possible ,,No-Rates Cut,,!wE CAN SIMPLY TELL THE SAME REASON trading stocks,indices! Simple: Economy under big inflation pressure.
2 approaches:Conservative and agressive entry. Where breakout traders enter,where others put their takeprofits,where others put stops: Thats my entry.Simple.
Near details ,please take a look at the chart above
Why we think SBC Medical Group is set for a rebound soon.Executive Summary:
SBC Medical Group Holdings Incorporated has emerged as one of the more compelling names in the post-SPAC public company landscape. Having successfully completed its business combination with Pono Capital Two, Inc. on 17 September 2024, the Japan-based aesthetic medical services provider now trades on Nasdaq under the ticker “SBC”. The SPAC merger valued the company at approximately USD1 billion and provided it with over USD11.7 million in net proceeds; capital that SBC intends to deploy strategically for international growth and asset diversification.
Key Investment Pointers:
At the heart of SBC Medical’s proposition is its extensive network of franchised and managed clinics in Japan, with forays into Vietnam and the United States. The company offers management services to cosmetic surgery and aesthetic dermatology clinics under the renowned “Shonan Beauty Clinic” brand, covering procurement, HR, customer loyalty, and more.
The SPAC listing has provided it with both visibility and liquidity at a time when demand for aesthetic healthcare continues to rise across Asia and globally.
The Group’s third-quarter results, covering the period ended 30 September 2024, underscore its operational strength. SBC posted total net revenues of USD53.1 million for Q3, a 12.3% year-on-year increase. Gross profit surged to USD43.2 million, yielding a gross margin of over 81%, reflective of the company’s high-margin service model.
While operating income dipped compared to the prior year due to a one-off non-cash stock-based compensation expense of USD12.8 million, net income for the nine-month period still rose to USD40.1 million, a 60% increase compared to the same period in 2023.
Its balance sheet tells a story of disciplined financial management and scalability. As of 30 September 2024, SBC held USD137.4 million in cash and cash equivalents, up from USD103 million at the end of 2023.
The company also saw a significant reduction in total liabilities from USD115 million to USD91 million, while shareholder equity rose to over USD205 million. These figures point to a solid capital base capable of absorbing strategic investments and macroeconomic volatility.
In a move that has drawn considerable market attention, SBC Medical has also initiated a diversification of its corporate treasury into Bitcoin.
With the cryptocurrency having rebounded strongly to the USD86,000 level, SBC’s entry appears both timely and calculated. While the exact volume of the acquisition has yet to be disclosed publicly, the Group has indicated that its Bitcoin holdings are part of a broader strategy to preserve purchasing power in a globally inflationary environment and align itself with digital-native investors. The decision places SBC in the company of firms like MicroStrategy and Tesla, which have similarly sought value preservation through Bitcoin.
The strategic trifecta of a successful SPAC listing, strong underlying financials, and an asset diversification play into Bitcoin positions SBC Medical favourably in the eyes of institutional investors. With Q4 results expected soon and a bullish cryptocurrency market supporting sentiment, SBC could well be on the cusp of a re-rating by the market.
If its fundamentals remain sound—as recent filings suggest—they may indeed ride the same momentum wave currently lifting digital assets and new-age healthcare stocks alike.
NAS100USD Buy Idea: Bullish Momentum Targets 20705🚀 OANDA:NAS100USD Buy Idea: Bullish Momentum Targets 20705 💹 - 24h expiry
OANDA:NAS100USD - We look to Buy at 20025
Stop Loss: 19825
Target 1: 20705
Target 2: 20730
Resistance: 20234, 20705, 20730
Support: 20025, 19423, 19125
Technical Setup:
📈 Continued upward momentum from 19424 resulted in the pair posting net daily gains yesterday .
⚠️ Overbought extremes indicate scope for mild selling at the open, but losses should remain limited .
🔑 Medium-term bias remains bullish .
🏁 Key resistance level at 20705 .
📰 News Sentiment
📊 Recent sessions show a bullish uptick in News Sentiment (Red Line), aligning with the price movement (Blue Line).
🌟 Positive sentiment (Red Line) is extending higher, suggesting further upside potential in the short term.
Risk Disclaimer
The trade ideas beyond this page are for informational purposes only and do not constitute investment advice or a solicitation to trade. This information is provided by Signal Centre, a third-party unaffiliated with OANDA, and is intended for general circulation only. OANDA does not guarantee the accuracy of this information and assumes no responsibilities for the information provided by the third party. The information does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
You accept that you assume all risks in independently viewing the contents and selecting a chosen strategy.
Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, Oanda Asia Pacific Pte Ltd (“OAP“) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore customers should contact OAP at 6579 8289 for matters arising from, or in connection with, the information/research distributed.
Will NASDAQ Rally Continue? Technical Analysis & Trade Idea.NASDAQ NAS100 (4H Chart) Analysis 📊📈
The NASDAQ NAS100 is showing strong bullish momentum on the 4-hour chart. The chart suggests a continuation of the uptrend, with a potential move toward the 21,013.0 target. 🚀
Key Levels to Watch 👀
Support Levels:
19,750.9: Near the 61.8% Fibonacci retracement, this level has seen strong buying interest.
19,405.8: The 100% Fibonacci retracement, marking the swing low and a critical support zone.
Resistance Levels:
20,209.4: The 0% Fibonacci retracement, acting as immediate resistance.
20,611.2: The 50% Fibonacci extension, a key target for bullish continuation.
21,013.0: The 100% Fibonacci extension, representing the ultimate bullish target in this trend.
Volume Profile Insights 📉
The Volume Profile shows heavy trading activity between 19,800–20,000, confirming strong support in this range. Above 20,200, trading volume thins out, suggesting that a breakout could lead to a quick rally toward 21,000.
Momentum and Indicators ⚡
Trend: The index is in a clear uptrend, forming higher highs and higher lows since the recent swing low.
Fibonacci Confluence: The alignment of the 50% retracement and Volume Profile support strengthens the bullish outlook.
Curved Arrow Projection: A pullback to the 19,800–19,750 zone is likely before the next leg higher toward 21,013.0.
Social Media Sentiment 🌐
Twitter: Analysts are optimistic, citing strong tech sector performance and easing interest rate fears. Many traders are eyeing the 21,000 level as the next milestone.
Reddit: Discussions emphasize the importance of the 19,800 support zone, warning that a break below this level could invalidate the bullish setup.
Conclusion 📝
The NASDAQ NAS100 is set for a bullish continuation, with key support at 19,750–19,800 and resistance at 20,209.4 and 21,013.0. Watch for a potential pullback to the 50% Fibonacci retracement before the next upward move. A break below 19,750 could signal a shift in momentum, while a breakout above 20,209.4 would confirm the bullish trend. 🚀
Disclaimer: This analysis is for informational purposes only and not financial advice. Always do your own research and consult a professional before trading. 📢
Caution on Crypto, Tech, SPXI know its a mess, this is just for me anyway.
I tend to overcomplicate things so now then, lets over simplify for my monkey brain:
Trend line broken = Warning, thing are likely to change ( even though you didnt get the bull market you wanted)
Watch said trend retest, look for weakness, struggling price action
selling on the retest of the top lows last time would offer you 5% off the peako top, (Thats really good!! stop being a perfectionist)
I am very much frustrated with this market, never got the crazy part I was waiting for. But the lack of euphoria is really not that unreasonable when you think about what has been goin on the past 5 years. Everyone is poorer liquidity has been super tight to curb inflation and we still got NASDAQ:NDX up 150% Coinbase NASDAQ:COIN did a 10x and I still am not happy(likely due to the max pain trade of my life COINBASE:ETHUSD ). I have realized that I have been hoping for another 2018 bull run. It may or may not happen, but I can't expect any market to reflect that in any significant way. Markets are much more dynamic than I give them credit for sometimes. They will rhyme but often in ways you do not expect and will not be made clear until that little bastard hindsight kicks in, showing you how obvious it was.
Today analysis for Nasdaq, Oil, and GoldNasdaq
The Nasdaq closed higher, forming a gap up on the daily chart. It showed a strong, one-directional rebound up to the 5-week moving average on the weekly chart.
Since the 5-week MA overlaps with the 60-week MA, it's unlikely to break through easily without a short-term correction.
On the daily chart, the MACD has formed a golden cross, meaning that even if a pullback occurs, the strategy should remain buy-on-dip oriented.
There is still an open gap down to 19,960, which could be filled at any time—so it's important to consider the possibility of a retest of that level. If the gap is filled, that area could be a good support zone to buy from.
On the 240-minute chart, strong buying momentum entered around the zero line, confirming a breakout after basing in a range. Therefore, buying on pullbacks remains the preferred approach in this structure.
Crude Oil
Crude oil continued its upward move, closing higher on the daily chart.
With strong support around the $68 level, the market could potentially rise toward the $70 zone, and possibly test resistance between $70–$71, which is a key area to watch closely.
Overall, traders should continue to buy on dips, but be cautious with chasing long positions above $70. If taking short positions, they should be managed with tight stop-losses.
On the 240-minute chart, oil appears to be in the midst of a third wave rally, so any short positions should be considered above $70, while buying pullbacks remains valid.
Current Middle East tensions and U.S. sanctions on Venezuelan oil are contributing to a supply risk premium in oil prices.
Since the market is recovering from the lows and showing a positive technical setup, short trades should be managed carefully with proper risk control.
Gold
Gold closed lower, remaining within its range-bound structure. On the daily chart, gold is currently trading between the 3-day and 5-day MAs above, and the 10-day MA below, forming a narrow consolidation zone. This makes sell-at-highs and buy-at-lows strategies effective.
Since there's room for a pullback to the 5-week MA on the weekly chart, chasing longs is not advised. If the MACD crosses below the signal line, this could create a bearish divergence, leading to potential sharp downside, so caution is warranted.
On the 240-minute chart, the MACD is failing to break above the signal line and continues to decline. However, since the signal line remains above the zero line, a rebound attempt is likely, even if the MACD dips below zero.
Given the current slope and distance, it's unlikely that a golden cross will form soon. Also, traders should keep in mind that major economic data such as GDP and PCE reports are scheduled later this week, which could influence market direction.
If you can understand the daily chart structure, you can better anticipate intraday high/low ranges and potential wave patterns. Make it a habit to perform thorough daily chart analysis each day, and prepare a trading scenario that suits the market’s behavior. As always, questions are welcome.
Wishing you a successful trading day!
If you like my analysis, please follow me and give it a boost!
For additional strategies for today, check out my profile. Thank you!
MNQ!/NQ1! Day Trade Plan for 03/24/2025MNQ!/NQ1! Day Trade Plan for 03/24/2025
*LAST UPDATE FOR THIS WEEK*
📈20370 20420
📉20140 20090
Like and share for more daily NQ levels 🤓📈📉🎯💰
*These levels are derived from comprehensive backtesting and research and a quantitative system demonstrating high accuracy. This statistical foundation suggests that price movements are likely to exceed initial estimates.*
Nasdaq - The Most Decisive Point Ever!Nasdaq ( TVC:NDQ ) might break below all structure:
Click chart above to see the detailed analysis👆🏻
After breaking above the major channel resistance trendline just a couple of months ago, the Nasdaq is now being dominated by bears and starting to break everything back to the downside. So far we didn't see any confirmation but the next couple of days will decide just everything.
Levels to watch: $20.000, $16.000
Keep your long term vision,
Philip (BasicTrading)
NASDAQ The recovery has officially started.Nasdaq (NDX) has been trading within a 2-year Channel Up and with today's opening, it broke above the Lower Highs trend-line of February's Bearish Leg. Even though the confirmed bullish reversal signal technically comes above the 1D MA50 (blue trend-line), we already have the early bottom signals.
First and foremost, the 1D RSI rebounding from the same oversold (<30.00) level where all major Higher Lows of the Channel Up did (August 05 2024, April 19 2024, October 26 2023). Every time the price reached its -0.5 Fibonacci extensions following such bottoms. Also each Bullish Leg tends so far to be smaller than the previous.
As a result, targeting a +24% rise (-3% less than the previous Bullish Leg) at 23500 is a very realistic Target technically, as it is considerably below the -0.5 Fibonacci extension.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
Zai Lab (ZLAB) – Biotech Growth & Profitability PathCompany Overview:
Zai Lab NASDAQ:ZLAB , a leading Chinese biotech firm, is on track for non-GAAP profitability by Q4 2025, driven by strong revenue growth & cost management.
Key Catalysts:
Financial Discipline & Expansion 💰
Operating losses fell 45% in Q4 2024, highlighting cost efficiency while scaling operations.
Analysts project $2 billion in annual revenue by 2028, reinforcing long-term value creation.
Blockbuster Drug Pipeline 💊
VYVGART generated $93.6M in its first full launch year, demonstrating strong adoption.
KarXT & bemarituzumab are key upcoming growth drivers, expanding ZLAB’s market footprint.
Investment Outlook:
Bullish Case: We are bullish on ZLAB above $34.00-$35.00, supported by financial execution & product expansion.
Upside Potential: Our price target is $54.00-$55.00, driven by strong product adoption & long-term growth trajectory.
🔥 Zai Lab – Unlocking the Future of Biotech Innovation. #ZLAB #Biotech #GrowthStocks
ATPC’s Selling Pressure Eases an Shows Signs of AccumulationAgape ATP Corporation (NASDAQ: ATPC) has seen a noticeable shift in its trading dynamics in recent weeks, as technical indicators point to a subsiding of selling pressure and early signals of possible fund accumulation. Following a volatile start to 2025, the stock is now displaying signs of base-building that could pave the way for a potential recovery.
From Capitulation to Consolidation
The counter experienced sharp declines earlier in the year, with a significant drop towards the $0.90 level in early March – a move that bore hallmarks of panic selling or capitulation. However, since hitting this low, the stock has stabilised and is now trading steadily within the $1.04–1.05 range. This stabilisation, coupled with narrower daily candle ranges and subdued volume, suggests that the worst of the selling pressure may now be behind.
Adding to this view are recent candlesticks with extended lower wicks – a classic signal of buying interest emerging on dips. The price action appears to be forming a technical base, potentially supported by buyers absorbing selling flows at lower levels.
Signs of Institutional Interest
While the price remains below its longer-term moving averages (MA120 at $1.38 and MA250 at $2.69), the flattening of shorter-term moving averages – MA5 ($1.034), MA10 ($1.031), and MA20 ($1.045) – is worth noting. These moving averages are now converging, hinting at a possible shift in momentum from bearish to neutral, or even bullish, if confirmed by subsequent price action.
A spike in volume observed in late February also lends credence to the idea of accumulation. Unlike speculative volume surges that tend to be followed by erratic moves, the stock’s ability to retain its gains and enter into consolidation territory suggests that stronger hands may be quietly positioning themselves.
The relatively modest turnover reading of 0.007 also supports this theory, indicating that accumulation may be occurring under the radar, without triggering undue volatility – a method often employed by institutional participants.
Key Levels to Monitor
The $1.00 level has emerged as a psychological and technical support zone, holding firm despite previous attempts to break lower. On the upside, traders and investors alike should watch for a clean break above the MA20 at $1.045, which could invite further momentum. A decisive move beyond the $1.10–1.15 resistance range, ideally accompanied by a pick-up in volume, would strengthen the bullish outlook and likely confirm fund-backed buying interest.
Conclusion
ATPC is currently at an interesting technical juncture. With selling pressure appearing to ease and signs of quiet accumulation beginning to surface, the stock may be transitioning from a downtrend into a potential recovery phase. Investors looking for early positioning may wish to monitor upcoming volume and price movements closely, particularly as the stock tests its short-term resistance levels.